Does Insurance Cover Wegovy? Employer Plans, Medicare, Medicaid, Prior Authorization and Appeals in 2026

Written by Diana Gangan. Updated October 26, 2026.

Insurance covers Wegovy for some people and not others, and the dividing line is rarely the drug itself; it is the reason on the prescription and the type of plan you have. Commercial employer plans cover Wegovy for weight loss roughly one time in five at large companies, nearly always with prior authorization. Medicare Part D is barred by law from paying for weight loss alone, but it does pay when Wegovy is prescribed to cut heart-attack risk or treat liver disease, and since July 2026 a federal pilot lets many beneficiaries get it for a flat $50 a month. Medicaid depends entirely on your state. If none of that applies, the manufacturer's self-pay price is $349 a month for the injection and $149 to $299 for the pill.

This guide walks through each type of coverage, the criteria insurers actually check, what to put in a prior authorization so it is approved the first time, how to appeal a denial, and when to stop fighting and pay cash.

Wegovy has four approved uses, and insurers treat them very differently. Chronic weight management is the original indication and the one most plans exclude or restrict. Reducing the risk of heart attack, stroke and cardiovascular death in adults with heart disease and overweight was added in March 2024; this is a cardiology indication and is covered far more often, including by Medicare. Treating metabolic dysfunction-associated steatohepatitis (MASH, a form of fatty liver disease) with moderate to advanced scarring was added in August 2025. And the once-daily pill, approved in December 2025, carries the weight management indication. The same vial, prescribed for heart disease rather than for weight, can go from denied to covered. That is not a loophole; it is how the label is written. What the drug does in each of those conditions is explained in what Wegovy does.

Employer figures come from the Kaiser Family Foundation's 2025 employer survey. Medicare rules are current as of October 2026; the Bridge pilot was announced by CMS in spring 2026 and extended to run through December 2027.

Almost every plan that covers Wegovy requires prior authorization, which means your prescriber must send evidence that you meet the plan's criteria before the pharmacy can fill it. The criteria are not secret; they are published in each plan's clinical policy and they are remarkably similar across insurers because they copy the drug label.

For the cardiovascular indication the checklist changes: established heart disease (prior heart attack, stroke, or peripheral artery disease) plus BMI of 27 or more, with no requirement for a lifestyle program. For MASH, a liver diagnosis with fibrosis stage F2 or F3, usually by imaging or biopsy.

Denials are mostly paperwork failures, not medical judgments. Before your appointment, pull together your weight history, any previous diet programs with dates, your lab results and your diagnoses. Ask the clinic to record your BMI at the visit and to list every weight-related condition in the note, including ones that feel minor, such as prediabetes or sleep apnea. If you have ever tried a weight-loss program, an app with a dietitian, or a prescription weight drug, make sure it is in the chart with dates. If you have heart disease, ask whether Wegovy should be prescribed for cardiovascular risk reduction rather than for weight, because the coverage pathway is cleaner. Then ask the clinic to submit the prior authorization electronically with the chart notes attached; a bare form with no documentation is the most common reason for a first denial.

Every denial letter must state the reason and the appeal deadline, usually 180 days for employer plans. Read the reason, because it tells you what to fix. The appeal has levels.

A denial because of a plan exclusion is different from a denial for not meeting criteria. If the plan document says weight-loss drugs are not covered, no appeal will add them; the route is your employer's benefits team at renewal time. If the denial says you failed to meet criteria, appeals succeed often enough to be worth the hour it takes.

The first door is the oldest: the Medicare Modernization Act of 2003 excluded drugs for weight loss from Part D, and that exclusion is still in force. The second door opened in March 2024, when the FDA added the cardiovascular indication and CMS confirmed Part D plans could cover Wegovy for that use; most plans now do, with prior authorization requiring documented heart disease. MASH was added as a covered reason in 2025. The third door is the Medicare GLP-1 Bridge, a pilot that began on July 1, 2026 and runs to December 31, 2027. It sits outside your Part D plan: prior authorization goes through a central CMS contractor, your prescriber does not need to be a Medicare provider, and you pay a flat $50 at the pharmacy regardless of dose. You qualify with a BMI of 35 or more, or 27 or more with a qualifying condition such as heart disease or prediabetes. The $50 does not count toward your Part D deductible or the $2,100 out-of-pocket cap, and Extra Help subsidies do not apply. If you are already on Wegovy, your prescriber can attest that you met the criteria when you started.

Medicaid programs must cover Wegovy's active ingredient for diabetes (as Ozempic) but may choose whether to cover anti-obesity drugs. In 2025 about a dozen states did, and the list has moved in both directions since: some states added coverage with prior authorization, others dropped it when the bills came in. Your state's Medicaid preferred drug list is public and searchable; look for Wegovy under anti-obesity agents and read the prior authorization criteria, which usually mirror the commercial ones above. If your state covers it only for the cardiovascular or MASH indications, the same prescription-reason logic applies.

The list price of Wegovy injection is about $1,349 a month and almost nobody pays it. Novo Nordisk's self-pay program through NovoCare and the federal TrumpRx site charges $349 a month for every injection dose from 0.25 mg to 2.4 mg, with the first two fills of the two starting doses at $199. Wegovy HD (7.2 mg) is $399. The pill is priced by dose: $149 for the lowest strength rising to $299 for the highest. These are cash prices, available to anyone without using insurance, and they are often lower than an insured copay with a high deductible. Novo has also announced that list prices will drop to $675 from January 2027, which matters mainly for insured people whose deductibles are based on list price. The current programs, the savings card for commercially insured patients and how GoodRx fits in are in Wegovy savings card and coupon guide.

If the injection's $349 is out of reach, the pill at $149 for the starting dose is the cheapest branded semaglutide for weight loss, with the trade-offs described in Wegovy pill vs injection.

Coverage of the two is similar; plans that cover one usually cover both, often with a preference for whichever the pharmacy benefit manager negotiated a better rebate on that year. Several large PBMs switched preferred status between Wegovy and Zepbound during 2025 and 2026, so a plan that covered Zepbound in January may prefer Wegovy by July. If your plan prefers one, the other will need an exception request. The clinical comparison is in Zepbound vs Wegovy. For Medicare's Bridge pilot, both Wegovy and the Zepbound KwikPen are included at the same $50.

Only if you have type 2 diabetes. Ozempic and Wegovy are the same molecule, and Ozempic is covered by almost every plan including Medicare, but only for diabetes. Prescribing Ozempic for weight loss and coding it as diabetes is insurance fraud, and plans now routinely check for a diabetes diagnosis and HbA1c before approving it. If you do have diabetes, Ozempic is usually the easier path; the differences in dose and labeling are in Wegovy vs Ozempic.

Whether insurance covers Wegovy depends on the plan type and the reason on the prescription. Employer coverage for weight loss is a coin flip at best and always needs prior authorization with documented BMI, comorbidities and a lifestyle attempt. Medicare pays for heart disease and MASH, and the GLP-1 Bridge pilot now pays for obesity itself at $50 a month until the end of 2027. Medicaid is a state lottery. If every door is closed, the manufacturer's $349 injection and $149 to $299 pill prices are the real cost, and for many people with high-deductible plans they are also the cheapest route. Whatever you do, get the documentation right the first time; most denials are missing paperwork, not medical refusals. What you can expect once you start is in how long Wegovy takes to work and how much weight you can lose on Wegovy.

Coverage rules change frequently. Figures are current as of October 2026; confirm with your plan's formulary and prior authorization policy.